BioScreening - organic compounds for screening

25.02.2004 February 2004 News Archive
Yamanouchi Pharmaceutical Co and Fujisawa Pharmaceutical Co., Ltd announced that they have reached a basic agreement to merge on April 1, 2005. The newly combined company is expected to gain a highly competitive edge in the global pharmaceutical market and will aim at developing into a global player. Pooled resources will rank the new company 17th in the global pharmaceutical market with sales of approximately 800 billion yen. PR-JCNN  2/24/04

Merck & Co.,one of the world's leading research-based pharmaceutical companies, and Aton Pharma, a privately held  company focusing on development of novel treatments for cancer and other serious diseases, announced that they have entered into a definitive agreement under which Merck will acquire Aton. Under the terms of the agreement, Merck will acquire 100 percent of the equity of Aton and Aton will become a wholly owned subsidiary of Merck. PR-Merck 2/23/04

IDBS announced that its flagship application, ActivityBase has been named a Top 5 Chemistry Product of the year by Scientific Computing & Instrumentation magazine, based on reader response. IDBS has also recorded unprecedented levels of interest in the chemistry aspects of ActivityBase during the past year. Over eighty biotechnology companies now employ ActivityBase for managing both their chemical and biological data, and it is widely recognized as the application of choice for biotechnology companies that require both data integration and scalability in their data management platforms PR/IDBS 2/18/04

Chiesi Farmaceutici and NiKem Research have announced details of a collaboration for a discovery program in the respiratory area. This agreement follows another research agreement that resulted in the identification of an optimized lead currently under development for the prevention and treatment of Alzheimer's disease. PR/ Nikemi  2/18/04

Evotec OAI , a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, and Toray Industries, announced a screening and medicinal chemistry collaboration to identify drug candidates interacting with one of the drug targets discovered in the genomic novel drug discovery project in Toray. Evotec OAI will use its state-of-the-art computational chemistry platform to virtually screen its database of over 3 million compounds to identify structures that are predicted to interact with the target. PR - Evotec 2/11/04

Tecan US, a leader in the Life Sciences supply industry, has introduced Cellerity, a fully automated high-throughput cell and protein production system for cell culture maintenance, cell-line expansion and harvesting. Cellerity is based on Tecan's successful next-generation Freedom EVO robotic liquid handling platform, and offers a high-throughput solution for achieving a timely, reliable and consistent supply of cells for cell-based assays, helping to overcome a significant, industry-wide bottleneck. PR-Tecan 2/2/04
More bioscreening news...

new | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003